|
CytoDyn hopes for Breakthrough label for HIV
therapy
February 2017
SHARING OPTIONS:
VANCOUVER, Wash.—CytoDyn Inc. has filed a
request with the FDA for Breakthrough Therapy Designation for PRO 140 for HIV-1 infection in treatment-experienced patients with virologic failure. Results
from four completed and ongoing clinical trials suggest PRO 140 can address unmet medical needs for HIV-1 patients with uncontrolled viral load despite
conventional antiretroviral therapy.
Dr. Nader Pourhassan, CytoDyn’s president and CEO, said:
“Investigators from several sites have requested continued access to PRO 140 to allow patients to continue deriving clinical benefit and maintain HIV-1
viral suppression after the end of treatment in the CD02 Phase 3 combination therapy study. Seven patients have entered the rollover study to receive
continued access to PRO 140 after the completion of the 25-week treatment period in this study. Additionally, 10 patients in the ongoing Phase 2b extension
arm of Monotherapy trial have shown suppressed viral load for two years.”
Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|